

# Financial Review **FIRST HALF-YEAR**

27 July 2017

CLARIANT INTERNATIONAL LTD

Rothausstrasse 61  
4132 Muttenz  
Switzerland

what is precious to you?

**CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

First Half 2017 (unaudited)

27 July 2017

Page 1 of 16

**Key Financial Group Figures**

	First Half			
	2017		2016	
	CHF m	% of sales	CHF m	% of sales
Sales	3 132	100.0	2 899	100.0
Local currency growth (LC):	9%			
<i>Organic growth</i> <sup>1</sup>	5%			
<i>Acquisitions/divestitures</i>	4%			
Currencies	–1%			
Gross profit	953	30.4	918	31.7
EBITDA before exceptional items*	482	15.4	444	15.3
EBITDA*	412	13.2	395	13.6
Operating income before exceptional items*	344	11.0	316	10.9
Operating income	274	8.7	267	9.2
Net income total	153	4.9	128	4.4
Basic earnings per share (CHF/share)	0.44		0.38	
Adjusted earnings per share (CHF/share)*	0.66		0.55	
Operating cash flow	116		208	
<b>Other key figures total Group:</b>	<b>30.06.2017</b>		<b>31.12.2016</b>	
Net debt	1 584		1 540	
Equity (including non-controlling interests)	2 647		2 546	
Gearing	60%		60%	
Number of employees	18 180		17 442	

<sup>1</sup> Throughout this statement the term "organic growth" is used to mean volume and price effects excluding the impacts of changes in FX rates and acquisitions/divestitures.

\* See Definition of Terms of Financial Measurements on pages 4 and 5.

**CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

First Half 2017 (unaudited)

27 July 2017

Page 2 of 16

**FINANCIAL DISCUSSION – FIRST HALF-YEAR****Sales and Net Results First Half 2017**

**Sales** increased 9 % in local currency, of which 5 % organic growth. In Swiss francs sales increased by 8 %, compared to the previous year.

The **gross margin** for the first half of 2017 was 30.4 % of sales compared to 31.7 % recorded in the prior-year period.\*

**Selling, general and administrative costs** remained at 20.0 % of sales, which for 2017 includes the SG&A of the acquired companies Kel-Tech Inc. and X-Chem LLC.\*

**Research and development costs** remained with CHF 104 million in the first half of 2017 at a comparable level to the previous year at CHF 106 million.\*

**Income from associates and joint ventures** of CHF 49 million in the first half of 2017 was above the level of the previous year (CHF 34 million) driven by the CHF 10 million asset step-up effect related to the consolidation of the Süd-Chemie India Pvt Ltd. joint venture.

The **net financial result** was CHF -69 million for the first half of 2017. Before foreign currency impacts, the financial result improved to CHF -40 million in the first half of 2017 from CHF -54 million in the first half of 2016. Changes in the debt profile, including the repayment of a EUR 500 million Eurobond in January 2017, were the main drivers for the decrease in financial expenses.

**Tax expense** of CHF 52 million was recorded in the first half of 2017 compared to CHF 50 million tax expense recorded in the prior-year period. The effective tax rate is lower than in the prior-year period due in part to increased profitability in lower tax jurisdictions.

**Net income** amounted to CHF 153 million in the half year of 2017, which was above the CHF 128 million net income reported in the same period of 2016.

\* Includes restructuring, impairment and transaction-related costs and gain/loss from the disposal of activities not qualifying as discontinued operations. See details on page 4.

**CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

First Half 2017 (unaudited)

27 July 2017

Page 3 of 16

**Balance Sheet Key Figures – June 2017**

**Total assets** decreased to CHF 7.721 billion as of 30 June 2017 from CHF 8.365 billion at the end of 2016 mainly due to the decrease in current assets driven by lower cash after repaying the bond issued in 2012 in the amount of EUR 500 million.

**Investments in associates and joint ventures** decreased to CHF 433 million from CHF 516 million mainly due to the change of the scope of consolidation of Süd-Chemie India Pvt Ltd. (SCIL) and dividends received from Infraser companies in Germany. As per 1 April 2017 SCIL is a fully consolidated company (see details in Note 5).

**Near cash assets** decreased to CHF 40 million from CHF 277 million. They include short-term deposits with an original maturity between 90 and 365 days.

**Current financial debts** decreased to CHF 309 million at the end of June 2017 from CHF 957 million at the end of December 2016. A bond issued in 2012 in the amount of EUR 500 million and a bond issued in 2011 in the amount of CHF 100 million reached maturity and were repaid.

**Equity** increased to CHF 2.647 billion at the end of June 2017 from CHF 2.546 billion at the end of 2016. This was mainly due to the net profit for the period amounting to CHF 153 million, to treasury shares transactions amounting to CHF 86 million, to the increase in non-controlling interest amounting to CHF 98 million resulting from the change of scope of consolidation of SCIL (see details in Note 5) and the combined effect of actuarial losses on retirement benefit obligations and a positive return on pension plan assets amounting to a positive CHF 19 million, net of deferred tax and effects.

The positive effects on equity as of end of June 2017 were partially offset by a distribution from capital contribution reserves of CHF 148 million, by CHF 4 million dividends paid to non-controlling interests and by the effect of employee services amounting to CHF 8 million. In addition, there were the negative currency translation differences amounting to CHF 98 million and the effect of a cash flow hedge amounting to CHF 1 million.

**Net debt** increased to CHF 1.584 billion at the end of June 2017, from CHF 1.540 billion at the end of 2016. This figure includes current and non-current financial debts, cash and cash equivalents, near cash assets and financial instruments with positive fair values reported under other current assets.

**Gearing**, which reflects net financial debt in relation to equity including non-controlling interests remained at the same level of 60% as at the end of June 2017 and December 2016.

**Cash Flow**

**Cash flow** from operating activities before changes in working capital and provisions for the first half of 2017 was CHF 339 million compared to CHF 389 million for the first half of 2016.

**Working capital** increased by CHF 223 million in the first half of 2017, compared with an increase of CHF 181 million in the first half of 2016.

**Cash flow from operating activities** was a positive CHF 116 million for the first half-year of 2017 compared to a positive CHF 208 million for the first half-year of 2016.

**Investments in PPE** were CHF 85 million for the first half-year of 2017 compared to CHF 129 million for the first half-year of 2016.

**Transactions with non-controlling interests** for the first-half year of 2017 relate to the change of the scope of consolidation of SCIL (see details in Note 5).

**Financing activities** mainly include the sale and purchase of treasury shares, distributions to the shareholders of Clariant and to non-controlling interests, proceeds from and repayments of financial debt, and the related interests paid and received.

**CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

First Half 2017 (unaudited)

27 July 2017

Page 4 of 16

**DEFINITION OF TERMS OF FINANCIAL MEASUREMENTS (UNAUDITED)**

The following financial measurements are supplementary financial indicators. They should be considered in addition to, not as a substitute for, operating income, net income, operating cash flow and other measures of financial performance and liquidity reported in accordance with International Financial Reporting Standards (IFRS).

**EBITDA**

– (Earnings Before Interest, Taxes, Depreciation and Amortization) is calculated as operating income plus depreciation of PPE, plus impairment and amortization of intangible assets, and can be reconciled from the Condensed Financial Statements as follows:

**EBITDA**

	<b>First Half</b>	
<i>CHF m</i>	<b>2017</b>	<b>2016</b>
Operating income	274	267
+ Depreciation of PPE	108	101
+ Impairment	–	–
+ Amortization of intangible assets	30	27
<b>EBITDA</b>	<b>412</b>	<b>395</b>

**EBITDA before exceptional items**

– is calculated as EBITDA plus expenses for restructuring, impairment and transaction related costs less impairment and gain/ loss on disposals.

**EBITDA before exceptional items**

	<b>First Half</b>	
<i>CHF m</i>	<b>2017</b>	<b>2016</b>
EBITDA	412	395
+ Restructuring, impairment and transaction related costs*	70	49
– Impairment (reported under Restructuring, impairment and transaction related costs)	–	–
– Gain from the disposal of activities not qualifying as discontinued operations	–	–
<b>EBITDA before exceptional items</b>	<b>482</b>	<b>444</b>

**Operating income before exceptional items**

– is calculated as operating income plus restructuring, impairment and transaction related costs and gain/loss on disposals.

**Operating income before exceptional items**

	<b>First Half</b>	
<i>CHF m</i>	<b>2017</b>	<b>2016</b>
Operating income	274	267
+ Restructuring, impairment and transaction related costs*	70	49
– Gain from the disposal of activities not qualifying as discontinued operations	–	–
<b>Operating income before exceptional items</b>	<b>344</b>	<b>316</b>

\* Restructuring, impairment and transaction related costs 2017: CHF 70 million (2016: CHF 49 million), of which: Cost of goods sold CHF 4 million (2016: CHF 9 million); Selling, general and administrative costs CHF 59 million (2016: CHF 31 million); Research and development expenses CHF 7 million (2015: CHF 9 million).



**CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

First Half 2017 (unaudited)

27 July 2017

Page 5 of 16

**Adjusted earnings per share**

– is the earnings per share adjusted for the impact of exceptional items, assuming an adjusted income tax rate of 26% for the period (2016: 28%).

**Adjusted earnings per share**

	<b>First Half</b>	
<i>CHF m</i>	<b>2017</b>	<i>2016</i>
Operating income before exceptional items	344	316
+ Amortization of intangible assets	30	27
+ Finance income	9	4
– Finance costs	–78	–93
Adjusted income before taxes	305	254
– Adjusted income taxes	–79	–71
Adjusted net result	226	183
Thereof attributable to non-controlling interests	9	5
Thereof attributable to shareholders of Clariant Ltd.	217	178
Weighted average number of shares outstanding	327 476 876	323 819 880
<b>Adjusted earnings per share attributable to shareholders of Clariant Ltd (CHF/share)</b>	<b>0.66</b>	<b>0.55</b>

**Net debt**

– is the sum of current and non-current financial debt less cash and cash equivalents, near cash assets and financial instruments with positive fair values.

**Net debt**

<i>CHF m</i>	<b>30.06.2017</b>	<i>31.12.2016</i>
Non-current financial debt	1 912	1 908
+ Current financial debt	309	957
– Cash and cash equivalents	–591	–1 043
– Near cash assets	–40	–277
– Financial instruments with positive fair values	–6	–5
<b>Net debt</b>	<b>1 584</b>	<b>1 540</b>

**CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

First Half 2017 (unaudited)

27 July 2017

Page 6 of 16

**CONDENSED FINANCIAL STATEMENTS OF THE CLARIANT GROUP****Consolidated balance sheets**

ASSETS	30.06.2017		31.12.2016	
	CHF m	%	CHF m	%
<b>Non-current assets</b>				
Property, plant and equipment	2 151		2 205	
Intangible assets	1 737		1 700	
Investments in associates and joint ventures	433		516	
Financial assets	48		71	
Prepaid pension assets	9		36	
Deferred income tax assets	286		298	
<b>Total non-current assets</b>	<b>4 664</b>	<b>60.4</b>	<b>4 826</b>	<b>57.7</b>
<b>Current assets</b>				
Inventories	913		816	
Trade receivables	1 060		1 011	
Other current assets	399		344	
Current income tax receivables	48		41	
Near cash assets	40		277	
Cash and cash equivalents	591		1 043	
<b>Total current assets</b>	<b>3 051</b>	<b>39.5</b>	<b>3 532</b>	<b>42.2</b>
Assets held for sale	6	0.1	7	0.1
<b>Total assets</b>	<b>7 721</b>	<b>100.0</b>	<b>8 365</b>	<b>100.0</b>
<b>EQUITY AND LIABILITIES</b>				
	CHF m	%	CHF m	%
<b>Equity</b>				
Share capital	1 228		1 228	
Treasury shares (par value)	–11		–29	
Other reserves	–8		229	
Retained earnings	1 256		1 033	
<b>Total capital and reserves attributable to Clariant shareholders</b>	<b>2 465</b>		<b>2 461</b>	
Non-controlling interests	182		85	
<b>Total equity</b>	<b>2 647</b>	<b>34.3</b>	<b>2 546</b>	<b>30.4</b>
<b>Liabilities</b>				
<b>Non-current liabilities</b>				
Financial debts	1 912		1 908	
Deferred income tax liabilities	33		33	
Retirement benefit obligations	867		918	
Provision for non-current liabilities	179		157	
<b>Total non-current liabilities</b>	<b>2 991</b>	<b>38.7</b>	<b>3 016</b>	<b>36.1</b>
<b>Current liabilities</b>				
Trade and other payables	1 204		1 228	
Financial debts	309		957	
Current income tax liabilities	308		305	
Provision for current liabilities	262		313	
<b>Total current liabilities</b>	<b>2 083</b>	<b>27.0</b>	<b>2 803</b>	<b>33.5</b>
Liabilities directly associated with assets held for sale	–	–	–	–
<b>Total liabilities</b>	<b>5 074</b>	<b>65.7</b>	<b>5 819</b>	<b>69.6</b>
<b>Total equity and liabilities</b>	<b>7 721</b>	<b>100.0</b>	<b>8 365</b>	<b>100.0</b>

**CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

First Half 2017 (unaudited)

27 July 2017

Page 7 of 16

**Consolidated income statements**

	First Half			
	CHF m	2017 %	CHF m	2016 %
Sales	3 132	100.0	2 899	100.0
Costs of goods sold*	– 2 179	69.6	– 1 981	68.3
<b>Gross profit</b>	<b>953</b>	<b>30.4</b>	<b>918</b>	<b>31.7</b>
Selling, general and administrative costs*	– 624	20.0	– 579	20.0
Research and development*	– 104	3.3	– 106	3.7
Income from associates and joint ventures	49	1.6	34	1.2
<b>Operating income</b>	<b>274</b>	<b>8.7</b>	<b>267</b>	<b>9.2</b>
Finance income	9	0.3	4	0.1
Finance costs	– 78	2.5	– 93	3.2
<b>Income before taxes</b>	<b>205</b>	<b>6.5</b>	<b>178</b>	<b>6.1</b>
Taxes	– 52	1.6	– 50	1.7
<b>Net result</b>	<b>153</b>	<b>4.9</b>	<b>128</b>	<b>4.4</b>
<b>Attributable to:</b>				
Shareholders of Clariant Ltd	144		123	
Non-controlling interests	9		5	
<b>Basic earnings per share attributable to the shareholders of Clariant Ltd (CHF/ share):</b>	<b>0.44</b>		<b>0.38</b>	
<b>Diluted earnings per share attributable to the shareholders of Clariant Ltd (CHF/ share):</b>	<b>0.44</b>		<b>0.38</b>	

\* include Restructuring, impairment and transaction related costs and Gain from the disposal of activities not qualifying as discontinued operations. See details on page 5.



**CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

First Half 2017 (unaudited)

27 July 2017

Page 8 of 16

**Consolidated statements of comprehensive income**

	<b>First Half</b>	
<i>CHF m</i>	<b>2017</b>	<b>2016</b>
<b>Net income</b>	<b>153</b>	<b>128</b>
<b>Other comprehensive income:</b>		
<i>Remeasurements:</i>		
Actuarial gain/loss on retirement benefit obligations	-22	-149
Return on retirement benefit plan assets, excluding amount included in interest expense	50	40
<b>Total items that will not be reclassified subsequently to the income statement, gross</b>	<b>28</b>	<b>-109</b>
Deferred tax on remeasurements	-9	16
<b>Total items that will not be reclassified subsequently to the income statement, net</b>	<b>19</b>	<b>-93</b>
Net investment hedge	4	-3
Cash flow hedges	-1	-
Currency translation differences	-98	-48
Effect of the reclassification of foreign exchange differences on previously held net investments in foreign entities	-	2
<b>Total items that may be reclassified subsequently to profit and loss</b>	<b>-95</b>	<b>-49</b>
Deferred tax effect	-	-
<b>Total items that will be reclassified subsequently to the income statement, net</b>	<b>-95</b>	<b>-49</b>
<b>Other comprehensive income for the period, net of tax</b>	<b>-76</b>	<b>-142</b>
<b>Total comprehensive income for the period</b>	<b>77</b>	<b>-14</b>
<b>Attributable to:</b>		
Shareholders of Clariant Ltd	74	-20
Non-controlling interests	3	6
<b>Total comprehensive income for the period</b>	<b>77</b>	<b>-14</b>

## CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

First Half 2017 (unaudited)

27 July 2017

Page 9 of 16

## Consolidated statement of changes in equity

										First Half
			Other reserves							
	Total share capital	Treasury shares (par value)	Share premium reserves	Hedging reserves	Cumulative translation reserves	Total other reserves	Retained earnings	Total attributable to equity holders	Non- controlling interests	Total equity
CHF m										
Balance 31 December 2015	1 228	−34	1 448	−	−1 066	382	841	2 417	77	2 494
Net income						−	123	123	5	128
Net investment hedge					−3	−3		−3		−3
Remeasurements:										
Actuarial loss on retirement benefit obligations						−	−149	−149		−149
Return on retirement benefit plan assets, excluding amount included in interest expense						−	40	40		40
Deferred tax on remeasurements						−	16	16		16
Currency translation differences					−49	−49		−49	1	−48
Effect of the reclassification of foreign exchange differences on previously held net investments in foreign entities					2	2		2		2
Total comprehensive income for the period	−	−	−	−	−50	−50	30	−20	6	−14
Distributions			−129			−129		−129		−129
Dividends to non-controlling interests						−		−	−2	−2
Employee share & option scheme:										
Effect of employee services						−	−11	−11		−11
Treasury share transactions		5				−	19	24		24
Balance 30 June 2016	1 228	−29	1 319	−	−1 116	203	879	2 281	81	2 362
Balance 31 December 2016	1 228	−29	1 319	5	−1 095	229	1 033	2 461	85	2 546
Net income						−	144	144	9	153
Cash flow hedge				−1		−1		−1		−1
Net investment hedge					4	4		4		4
Remeasurements:										
Actuarial loss retirement benefit obligations						−	−22	−22		−22
Return on retirement benefit plan assets, excluding amount included in interest expense						−	50	50		50
Deferred tax on remeasurements						−	−9	−9		−9
Currency translation differences					−92	−92		−92	−6	−98
Total comprehensive income for the period	−	−	−	−1	−88	−89	163	74	3	77
Distributions			−148			−148		−148		−148
Dividends to non-controlling interests						−		−	−4	−4
Transaction with non-controlling interests						−		−	98	98
Employee share & option scheme:										
Effect of employee services						−	−8	−8		−8
Treasury share transactions		18				−	68	86		86
Balance 30 June 2017	1 228	−11	1 171	4	−1 183	−8	1 256	2 465	182	2 647

**CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

First Half 2017 (unaudited)

27 July 2017

Page 10 of 16

**Consolidated statements of cash flows**

	<b>First Half</b>	
<i>CHF m</i>	<b>2017</b>	<b>2016</b>
Net income	153	128
<b>Adjustment for:</b>		
Depreciation of property, plant and equipment (PPE)	108	101
Amortization of intangible assets	30	27
Impairment of working capital	7	13
Income from associates and joint ventures	-49	-34
Tax expense	52	50
Net financial income and costs	40	54
Other non-cash items	31	44
<b>Total reversal of non-cash items</b>	<b>219</b>	<b>255</b>
Dividends received from associates and joint ventures	44	62
Income taxes paid	-52	-38
Payments for restructuring	-25	-18
<b>Cash flow before changes in working capital and provisions</b>	<b>339</b>	<b>389</b>
Changes in inventories	-101	-55
Changes in trade receivables	-61	-57
Changes in trade payables	7	-91
Changes in other current assets and liabilities	-73	15
Changes in provisions (excluding payments for restructuring)	5	7
<b>Cash flow from operating activities</b>	<b>116</b>	<b>208</b>
Investments in PPE	-85	-129
Investments in financial assets, associates and joint ventures	-	-8
Investments in intangible assets	-16	-18
Changes in current financial assets and near cash assets	265	39
Sale of PPE and intangible assets	5	1
Acquisition of companies, businesses and participations	1	-50
Proceeds from the disposal of activities not qualifying as discontinued operations	8	-3
<b>Cash flow from investing activities</b>	<b>178</b>	<b>-168</b>
Purchase of treasury shares	-	-20
Sale of treasury shares	76	27
Distributions from the reserves to the shareholders of Clariant Ltd	-148	-129
Dividends paid to non-controlling interest	-4	-2
Transactions with non-controlling interests	58	-
Proceeds from financial debts	41	448
Repayments of financial debts	-695	-175
Interest paid	-66	-65
Interest received	9	4
<b>Cash flow from financing activities</b>	<b>-729</b>	<b>88</b>
Currency translation effect on cash and cash equivalents	-17	-21
<b>Net change in cash and cash equivalents</b>	<b>-452</b>	<b>107</b>
<b>Cash and cash equivalents at the beginning of the period</b>	<b>1 043</b>	<b>789</b>
<b>Cash and cash equivalents at the end of the period</b>	<b>591</b>	<b>896</b>

## NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

### 1. Basis of preparation of financial statements

These financial statements are the interim condensed consolidated financial statements (hereafter “the interim consolidated financial statements”) of Clariant Ltd, a company registered in Switzerland, and its subsidiaries (hereafter “the Group”) for the six-month period ended on 30 June 2017. They are prepared in accordance with the International Accounting Standard 34 (IAS 34 “Interim Financial Reporting”) and were approved on 26 July 2017 by the Board of Directors. These interim consolidated financial statements should be read in conjunction with the Consolidated Financial Statements for the year ended 31 December 2016 (hereafter “the annual financial statements”) as they provide an update of previously reported information. The accounting policies applied are consistent with the ones applied at year-end 2016.

The preparation of the interim consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, and disclosure of contingent liabilities at the date of the interim consolidated financial statements. If, in the future, such estimates and assumptions, which are based on the Management's best judgment at the date of the interim consolidated financial statements, deviate from the actual circumstances, the original estimates and assumptions will be modified as appropriate in the year in which the circumstances change.

### 2. New accounting standards

IFRS 9, Financial Instruments, addresses the classification, measurement and derecognition of financial assets and financial liabilities and introduces new rules for hedge accounting and a new impairment model. The complete version of IFRS 9 was issued in July 2014. It replaces the guidance in IAS 39 that relates to the classification and measurement of financial instruments. The standard is effective for accounting periods beginning on or after 1 January 2018. The Group is in the process of assessing the full impact of IFRS 9 on its consolidated financial statements. Material financial assets were reviewed and a valuation method was determined. The most important impact identified was the valuation at fair value of certain participations which will be done by way of level 3 valuations. It is currently expected that a positive effect will result from these valuations.

IFRS 15, Revenue from contracts with customers, deals with revenue recognition and establishes principles for disclosing useful information about revenue and cash flows arising from these contracts. This standard replaces IAS 18, Revenue, and IAS 11, Construction Contracts, and related interpretations. It is effective for accounting periods beginning on or after 1 January 2018. The Group is in the process of assessing the impact of IFRS 15 on its consolidated financial statements. In particular it was reviewed to what extent Clariant invoices goods and services that are distinct and would require a separate recognition. Furthermore, it was reviewed in intensive discussions with the Business if the timing of the revenue recognition is in line with requirements of the new standard with regard to the recognition over a period of time as opposed to the recognition at a point in time. Also, it was reviewed if there is a need to more accurately recognize the effect of volume discounts extended to customers and if the right of return had to be accounted for. As of now Clariant's conclusion is that distinct items of revenue are accounted for accordingly, that revenues are properly recognized either over time or at a point in time and that there are no significant rights of return granted. As a consequence it is estimated that the application of the recognition and valuation rules required will not have any material impact on the accounts of the Group.

### 3. Seasonality of operations

The Group operates in industries where significant seasonal or cyclical variations in total sales are not experienced during the financial year.

### 4. Fair value measurement

All derivative financial instruments held by the Group at the end of June 2017 are classified as “Level 2” as defined by IFRS 13 Fair Value Measurement.

On 1 October 2016 Clariant acquired from Arsenal Capital Partners 100 % of the shares of Kel-Tec Inc. for a total consideration of CHF 224 million, out of which CHF 203 million were paid in 2016 and CHF 21 million are considered as contingent consideration. If certain sales goals are met in 2017, an earn-out up to a maximum of CHF 35 million will become payable in 2018. The fair value of the contingent consideration was determined based on the business plans available at the year-end and it is currently unchanged.

**CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

First Half 2017 (unaudited)

27 July 2017

Page 12 of 16

**5. Change in the scope of consolidation**

As of 1 April, 2017 Clariant fully consolidated the Süd-Chemie India Pvt Ltd. (SCIL), which was until that time accounted for as a joint venture and as such was valued at equity. Clariant's share in SCIL is 50 %, while the other 50 % are owned by private investors in India.

In view of SCIL's significance for Clariant's Catalysis activities in Asia, management successfully renegotiated the joint venture contracts resulting in Clariant obtaining more influence in managerial decisions in a way that control was obtained in the sense of IFRS.

As no consideration was paid, nor any shares were purchased or sold, this transaction is treated as an acquisition without consideration. Prior to the full consolidation Clariant already owned 50 % of SCIL. In a first step this participation was revalued to fair value resulting in an income of CHF 10 million recognized in Income from associates and joint ventures in the income statement.

In a second step assets and liabilities of the company as per 1 April 2017 were included in the balance sheet, while the participation in the joint venture was derecognized. The co-owners' share in SCIL is recognized in non-controlling interests.

The table below shows the provisional allocation of the assets acquired and liabilities assumed:

CHF in million	
Non-current assets	101
Current assets	61
Cash and cash equivalents	58
<b>Total assets</b>	<b>220</b>
Interest-free liabilities	23
Interest-bearing liabilities	1
<b>Non-controlling interests</b>	<b>98</b>
<b>Net assets acquired for no consideration</b>	<b>98</b>

The preliminary goodwill of CHF 86 million (included in non-current assets) arising from the acquisition is attributable to a number of factors such as future growth potential in line with historical levels and cost synergies.

Had the change of scope of consolidation taken place on 1 January, 2017 Group sales would have been CHF 16 million higher and the Group operating result would have been CHF 3 million higher, while the net result available to Clariant shareholders would have remained unchanged.

**6. Restructuring, impairment and transaction-related costs**

During the first half-year of 2017, Clariant recorded restructuring expenses in the amount of CHF 30 million, mainly pertaining to projects in Europe, and transaction-related costs in the amount of CHF 40 million.

During the same period in the previous year, restructuring and transaction related costs amounted to CHF 49 million.

No impairment was recorded during first half-year of 2017 and 2016.

**7. Distribution from reserves**

On 20 March 2017, the General Meeting approved a distribution of CHF 0.45 per registered share from capital contribution reserves. On 27 March 2017, a distribution totaling CHF 148 million was made to Clariant shareholders.

**8. Repayments of financial liabilities**

On 24 January, 2017 a bond issued in 2012 in the amount of EUR 500 million (CHF 537 million) reached maturity and was paid back.

On 9 June, 2017 a bond issued in 2011 in the amount of CHF 100 million reached maturity and was paid back.

## CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

First Half 2017 (unaudited)

27 July 2017

Page 13 of 16

## 8. Business Area figures

First Half	Sales to 3rd parties				EBITDA before exceptionals				EBITDA			
CHF m	2017	2016	% CHF	% LC	2017	2016	% CHF	% LC	2017	2016	% CHF	% LC
Care Chemicals	796	750	6	8	139	148	-6	-6	119	144	-17	-17
Catalysis	321	285	13	11	76	53	43	41	72	52	38	36
Natural Resources	669	557	20	19	98	91	8	5	94	87	8	6
Plastics & Coatings	1346	1307	3	4	221	209	6	6	220	196	12	13
<b>Business Areas total</b>	<b>3 132</b>	<b>2 899</b>			<b>534</b>	<b>501</b>			<b>505</b>	<b>479</b>		
Corporate	—	—			-52	-57			-93	-84		
<b>Total</b>	<b>3 132</b>	<b>2 899</b>	<b>8</b>	<b>9</b>	<b>482</b>	<b>444</b>	<b>9</b>	<b>9</b>	<b>412</b>	<b>395</b>	<b>4</b>	<b>4</b>

	Operating income before exceptionals				Operating income				Systematic depreciation of PPE	
CHF m	2017	2016	% CHF	% LC	2017	2016	% CHF	% LC	2017	2016
Care Chemicals	109	122	-11	-9	89	118	-25	-23	26	23
Catalysis	52	29	79	74	48	28	71	65	16	15
Natural Resources	70	74	-5	-7	66	70	-6	-9	17	12
Plastics & Coatings	184	170	8	8	183	157	17	17	33	34
<b>Business Areas total</b>	<b>415</b>	<b>395</b>			<b>386</b>	<b>373</b>			<b>92</b>	<b>84</b>
Corporate	-71	-79			-112	-106			16	17
<b>Total</b>	<b>344</b>	<b>316</b>	<b>9</b>	<b>9</b>	<b>274</b>	<b>267</b>	<b>3</b>	<b>3</b>	<b>108</b>	<b>101</b>

	Net working capital		Property, plant and equipment		Intangible assets	
CHF m	30.06.2017	31.12.2016	30.06.2017	31.12.2016	30.06.2017	31.12.2016
Care Chemicals	228	219	472	496	117	119
Catalysis	200	168	496	504	777	713
Natural Resources	273	248	326	343	533	555
Plastics & Coatings	567	504	509	527	259	265
<b>Business Areas total</b>	<b>1 268</b>	<b>1 139</b>	<b>1 803</b>	<b>1 870</b>	<b>1 686</b>	<b>1 652</b>
Corporate	-47	-52	348	335	51	48
<b>Total</b>	<b>1 221</b>	<b>1 087</b>	<b>2 151</b>	<b>2 205</b>	<b>1 737</b>	<b>1 700</b>

## 9. Business Area margins

First Half	Sales to 3rd parties		EBITDA before exceptionals		EBITDA	
in %	2017	2016	2017	2016	2017	2016
Care Chemicals	25.4	25.9	17.5	19.7	14.9	19.2
Catalysis	10.2	9.8	23.7	18.6	22.4	18.2
Natural Resources	21.4	19.2	14.6	16.3	14.1	15.6
Plastics & Coatings	43.0	45.1	16.4	16.0	16.3	15.0
<b>Total</b>	<b>100.0</b>	<b>100.0</b>	<b>15.4</b>	<b>15.3</b>	<b>13.2</b>	<b>13.6</b>

	Operating income b. exceptionals		Operating income	
in %	2017	2016	2017	2016
Care Chemicals	13.7	16.3	11.2	15.7
Catalysis	16.2	10.2	15.0	9.8
Natural Resources	10.5	13.3	9.9	12.6
Plastics & Coatings	13.7	13.0	13.6	12.0
<b>Total</b>	<b>11.0</b>	<b>10.9</b>	<b>8.7</b>	<b>9.2</b>

**CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

First Half 2017 (unaudited)

27 July 2017

Page 14 of 16

**10. Geographic information**

<b>Sales</b>					<b>First Half</b>	
<i>CHF m</i>	<b>2017</b>	<i>% of sales</i>	<b>2016</b>	<i>% of sales</i>	<i>CHF %</i>	<i>LC %</i>
EMEA	1325	42.3	1234	42.6	7	9
<i>of which Europe</i>	1102		1030		7	8
<i>of which Germany</i>	365		345		6	7
<i>of which Switzerland</i>	19		21		–10	–10
<i>of which MEA</i>	223		204		9	12
North America	623	19.9	541	18.7	15	14
<i>of which USA</i>	576		492		17	16
Latin America	412	13.2	427	14.7	–4	–3
<i>of which Brazil</i>	170		154		10	–5
Asia / Pacific	772	24.6	697	24.0	11	11
<i>of which China</i>	244		217		12	15
<i>of which India</i>	99		95		4	2
<b>Total</b>	<b>3132</b>	<b>100.0</b>	<b>2899</b>	<b>100.0</b>	<b>8</b>	<b>9</b>

**11. Condensed earnings per share data**

	<b>First Half</b>	
	<b>2017</b>	<b>2016</b>
<b>Net income attributable to shareholders of Clariant Ltd (CHF m)</b>	<b>144</b>	<b>123</b>
<b>Shares</b>		
<b>Number of registered shares at 30.06.2017 and 30.06.2016 respectively</b>	<b>331 939 199</b>	<b>331 939 199</b>
<b>Weighted average number of shares outstanding</b>	<b>327 476 876</b>	<b>323 819 880</b>
Adjustment for granted Clariant shares	1 267 185	1 126 188
Adjustment for dilutive share options	–	24 842
<b>Weighted average diluted number of shares outstanding</b>	<b>328 744 061</b>	<b>324 970 910</b>
<b>Basic earnings per share attributable to shareholders of Clariant Ltd (CHF/share)</b>	<b>0.44</b>	<b>0.38</b>
<b>Diluted earnings per share attributable to shareholders of Clariant Ltd (CHF/share)</b>	<b>0.44</b>	<b>0.38</b>



**CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

First Half 2017 (unaudited)

27 July 2017

Page 15 of 16

**12. Finance income and costs**

<b>Finance income</b>		<b>First Half</b>	
<i>in CHF m</i>		<b>2017</b>	<b>2016</b>
Interest income		7	4
Other financial income		2	–
<b>Total finance income</b>		<b>9</b>	<b>4</b>
<b>Finance costs</b>			
<i>in CHF m</i>		<b>2017</b>	<b>2016</b>
Interest costs		–43	–53
<i>thereof effect of discounting of non-current provisions</i>		–1	–
<i>thereof interest component of pension provisions</i>		–10	–9
Other financial expenses		–6	–5
Currency result, net		–29	–35
<b>Total finance costs</b>		<b>–78</b>	<b>–93</b>

**13. Foreign exchange rates**

<b>Rates used to translate the consolidated balance sheets (closing rate)</b>	<b>30.06.2017</b>	<b>31.12.2016</b>	<b>Change %</b>
1 USD	0.96	1.02	–6
1 EUR	1.09	1.07	2
1 BRL	0.30	0.31	–3
1 CNY	0.14	0.15	–7
100 INR	1.48	1.50	–1
100 JPY	0.86	0.87	–1

		<b>First Half</b>	
<b>Average sales-weighted rates used to translate the consolidated income statements and consolidated statements of cash flows</b>	<b>2017</b>	<b>2016</b>	<b>Change %</b>
1 USD	0.98	0.98	–
1 EUR	1.08	1.10	–2
1 BRL	0.31	0.27	15
1 CNY	0.14	0.15	–7
100 INR	1.52	1.46	4
100 JPY	0.88	0.88	–

**CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

First Half 2017 (unaudited)

27 July 2017

Page 16 of 16

**CLARIANT – WHAT IS PRECIOUS TO YOU?**

Clariant is a globally leading specialty chemicals company, based in Muttens near Basel/Switzerland. On 31 December 2016, the company employed a total workforce of 17 442. In the financial year 2016, Clariant recorded sales of CHF 5.847 billion for its businesses.

Clariant's corporate strategy is based on five pillars: focus on innovation through R&D, add value with sustainability, reposition the portfolio, intensify growth, and increase profitability.

The company reports in four Business Areas: Care Chemicals, Catalysis, Natural Resources, and Plastics & Coatings.

[www.clariant.com](http://www.clariant.com)

**Calendar of Corporate Events**

31 October 2017	Nine Months 2017 Sales and EBITDA
14 February 2018	Full-Year 2017 Results
19 March 2018	Annual General Meeting
25 April 2018	First Quarter 2018 Sales and EBITDA

**Your Clariant Contacts**

<b>Investor Relations</b>	Fax +41 61 469 67 67
Anja Pomrehn	Tel. +41 61 469 63 73
Maria Ivek	Tel. +41 61 469 63 73
<b>Media Relations</b>	Fax +41 61 469 69 99
Jochen Dubiel	Tel. +41 61 469 63 63
Thijs Bouwens	Tel. +41 61 469 63 63

**Disclaimer**

This document contains certain statements that are neither reported financial results nor other historical information. This presentation also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors that are beyond Clariant's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company's ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social, and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation, and consumer confidence, on a global, regional, or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this document. Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials.